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This case study describes our holistic approach of scaling up a microcarrier-based perfusion cell culture 
process for the production of a therapeutic enzyme directly from a 12L benchtop glass bioreactor to a 
commercial scale stainless steel bioreactor. Besides conventional scale-up challenges such as mixing, 
shear stress and mass transfer, the scale-up of this microcarrier-based cell culture process posed its own 
challenges, e.g. the original design of the commercial scale stainless steel bioreactor had difficulty 
suspending microcarriers. Additional challenges included achieving effective cell attachment after 
seeding, balancing microcarrier stratification and culture turbulence, and minimizing bubble shear stress 
and foaming. To mitigate risks and maximize the chance of success in scaling up this process within an 
aggressive project timeline, we carried out a series of studies to systematically tackle these challenges.  
 
First, physical modifications necessary to adapt the existing commercial scale stainless steel bioreactor for 
this microcarrier-based cell culture process, e.g. impeller, baffle and sparger designs, were implemented 
based on computation fluid dynamics (CFD) simulation, high speed imaging, and at scale bioreactor 
characterization. Second, 12L small scale bioreactor studies were performed in concert with simulation 
and mathematical modeling to define operating ranges for scale-dependent parameters for the commercial 
scale bioreactor. Third, strategies to mitigate potential negative effects of scale-dependent parameters on 
the commercial scale process such as stratification, turbulence and foaming were established and tested at 
the 12L scale.  
 
Through our systematic work using CFD simulation, mathematical modeling, bioreactor characterization, 
and small scale bioreactor experimentation, we were able to achieve comparable bioreactor performance 
including product quality in the first large scale run; this allowed us to meet an accelerated project 
timeline.  
